{"id":"mopv2-at-6-and-7-weeks-of-age","safety":{"commonSideEffects":[{"rate":null,"effect":"Mild fever"},{"rate":null,"effect":"Local irritation at injection site (if given as IPV)"},{"rate":null,"effect":"Vaccine-strain poliovirus shedding in stool"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mOPV2 contains a weakened (attenuated) form of poliovirus type 2 administered orally. When ingested, the vaccine replicates in the intestinal tract and stimulates both mucosal and systemic immune responses, including antibody production and T-cell immunity against poliovirus type 2. This vaccination at 6 and 7 weeks of age is part of routine childhood immunization schedules to provide early protection against polio.","oneSentence":"mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:51.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus type 2 in infants"}]},"trialDetails":[{"nctId":"NCT02643368","phase":"PHASE4","title":"Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-12","conditions":"Poliomyelitis","enrollment":760}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"mOPV2 at 6 and 7 weeks of age","genericName":"mOPV2 at 6 and 7 weeks of age","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus type 2 in infants.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}